Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

NCT02504892 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Study was terminated due to slow, insufficient accrual.

Conditions

Renal Cancer
Birt-Hogg-Dube Syndrome

Interventions

DRUG: Everolimus

Sponsor

National Cancer Institute (NCI)